Study guide

5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux

BONENT Certified Hemodialysis Nurse CHN

Track your progress as you read

Finished sections get a check mark.

1 Exam Orientation

1.1 Current CHN Exam Facts and Study Strategy

2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology

2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations

3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management

4 Individualized Nursing Care

4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral

5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry

5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR

6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters

6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention

7 Chapter 5: Cannulation Practice & Access Complications

7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management

8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring

8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment

9 Equipment and Laboratory Skills

9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results

10 Chapter 7: Acute Intradialytic Complications & Emergencies

10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss

11 Extended and Acute Treatment

11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation

12 Chapter 8: Nephrology Pharmacology in Hemodialysis

12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing

13 Home and Peritoneal Dialysis

13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care

14 Kidney Transplantation

14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes

15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing

15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety

16 Clinical Unit Management

16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care

17 Chapter 10: Supervision, Administration & Professional Practice

17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care

18 Professional Development

18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation

19 Environmental Hazards and Emergency Planning

19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions

5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux

Key Takeaways Explain This Topic AI

Dialyzer membrane, surface area, priming volume and labeled clearance must match the prescription and delivery device.

High efficiency describes small-solute transfer; high flux describes water permeability and middle-solute performance.

Unmodified AN69 can generate bradykinin in patients taking ACE inhibitors; check the specific product warning.

Precise UF control and appropriate fluid quality protect patients when using highly permeable membranes.

Last updated: October 2026

Dialyzer Characteristics, Membrane Biocompatibility & Flux

The dialyzer functions as the artificial kidney in extracorporeal blood purification. Its physical design, membrane biomaterial composition, surface area, and transport characteristics dictate clinical efficacy and patient safety. Understanding membrane biocompatibility, complement activation, flux classifications, and drug-membrane interactions enables the Certified Hemodialysis Nurse (CHN) to tailor dialyzer selection, avoid hypersensitivity reactions, and minimize chronic systemic inflammation in end-stage renal disease (ESRD).

Dialyzer Engineering and Hollow-Fiber Design

Modern capillary dialyzers contain 7,000 to 15,000 semipermeable capillary fibers encased in a clear polycarbonate housing.

Capillary Fiber Geometry: Each hollow fiber has an internal lumen diameter of 180 to 220 μ m \mu\text{m} μ m (considerably wider than human blood capillaries) and a wall thickness of 30 to 50 μ m \mu\text{m} μ m . The narrow lumen shortens the diffusion distance from flowing red blood cells to the membrane surface.

Surface Area ( A A A ): Ranges from 1.0 to 2.5 m 2 \text{m}^2 m 2 , chosen based on patient body surface area, total body water, and clearance goals.

Polyurethane Potting: Fibers are anchored at each cylinder end by polyurethane potting compound. The ends are cut flush, opening into blood distribution headers. This potting physically separates the blood compartment inside the fibers from the dialysate compartment surrounding them.

Priming Volume: The blood compartment volume is 60 to 120 mL , minimizing extracorporeal blood sequestration and reducing initiation hypotension.

Membrane Materials

Dialyzer membranes are classified by chemical composition:

Synthetic Polymers: The standard in contemporary practice. Includes polysulfone (PSu) , polyethersulfone (PES) , polyamide , polyacrylonitrile (PAN / AN69) , and polymethylmethacrylate (PMMA) . They feature an asymmetric wall with a thin inner selective skin supported by a sponge-like matrix, offering high mechanical strength, high hydraulic permeability, and superior biocompatibility.

Modified Cellulosic Membranes: Produced by substituting acetate or tertiary amino groups for reactive hydroxyl groups on natural cellulose (e.g., cellulose triacetate [CTA] , hemophan). This reduces complement activation while retaining a thin membrane wall.

Unmodified Cellulose: Historic membranes ( cuprophan ) contained abundant free hydroxyl ( − O H -OH − O H ) groups that triggered severe complement activation.

Biocompatibility and Inflammatory Cascades

Biocompatibility reflects the degree of biological interaction between circulating blood and the foreign dialyzer membrane. Exposure to bioincompatible surfaces unleashes systemic inflammatory cascades:

Complement Activation and Transient Leukopenia

Unmodified cellulose membranes trigger the alternative complement pathway , generating C3a and C5a anaphylatoxins .

Mechanism: C5a induces circulating neutrophils and monocytes to aggregate and adhere to vascular endothelium within pulmonary capillaries.

Clinical Course: During the first 15 to 30 minutes of hemodialysis, peripheral white blood cell count drops by 50% or more (transient intradialytic leukopenia). This pulmonary leukostasis causes ventilation-perfusion mismatch and mild arterial hypoxemia ( P a O 2 PaO_2 P a O 2 ​ drops 5 to 15 mmHg). By 60 minutes, leukocytes demarginate and return to circulation.

Cytokine Release

Contact with bioincompatible surfaces activates monocytes to release pro-inflammatory cytokines ( IL-1, IL-6, TNF- α \alpha α ). Chronic cytokine exposure causes persistent microinflammation, accelerating vascular calcification, muscle wasting, and malnutrition.

Life-Threatening Contact System Activation: AN69 and ACE Inhibitors

A critical, life-threatening contraindication exists between polyacrylonitrile (AN69) membranes and angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril, enalapril):

Mechanism: AN69 membranes carry a strong negative surface charge that activates Factor XII (Hageman factor) and prekallikrein upon blood contact, rapidly producing bradykinin .

Enzyme Blockade: Bradykinin is degraded by kininase II, which is identical to angiotensin-converting enzyme (ACE). ACE inhibitors block kininase II, preventing bradykinin breakdown.

Clinical Emergency: Bradykinin accumulates rapidly. Within 2 to 5 minutes of initiating dialysis, the patient develops a severe anaphylactoid reaction with facial angioedema, bronchospasm, abdominal cramping, and profound hypotension. Check the specific membrane instructions: unmodified AN69 has a serious ACE-inhibitor/bradykinin interaction; surface-treated products have different labeling.

Membrane Flux Classification and Operational Safeguards

Dialyzers are classified by water permeability ( K u f K_{uf} K u f ​ ) and middle-molecule clearance:

Low-Flux Dialyzers

K u f < 10 mL/hr/mmHg K_{uf} < 10\text{ mL/hr/mmHg} K u f ​ < 10 mL/hr/mmHg (typically 4 to 8 mL/hr/mmHg).

Small pores (< 2 nm); molecular weight cutoff < 5 , 000 Da < 5,000\text{ Da} < 5 , 000 Da .

Clears small solutes via diffusion; middle-molecule clearance is negligible ( β 2 \beta_2 β 2 ​ -microglobulin sieving S β 2 m ≈ 0 S_{\beta2m} \approx 0 S β 2 m ​ ≈ 0 ).

High-Flux Dialyzers

K u f ≥ 20 mL/hr/mmHg K_{uf} \ge 20\text{ mL/hr/mmHg} K u f ​ ≥ 20 mL/hr/mmHg (commonly 40 to 80 mL/hr/mmHg).

Larger pores (3 to 5 nm); molecular weight cutoff 20,000 to 30,000 Da .

High clearance of small solutes and middle molecules ( S β 2 m > 0.6 S_{\beta2m} > 0.6 S β 2 m ​ > 0.6 ), reducing dialysis-related amyloidosis.

Recommended Operating Requirements:

Volumetric UF Control: Closed-loop volumetric balancing systems are recommended to prevent uncontrolled fluid loss under high K u f K_{uf} K u f ​ .

Ultrapure Dialysate: Prevention of endotoxin backfiltration is required.

Backfiltration Dynamics and Endotoxin Safeguards

In high-flux dialyzers, blood pressure falls along the fibers due to internal resistance. Near the venous blood outlet, dialysate pressure can exceed blood pressure ( P d i a l y s a t e > P b l o o d P_{dialysate} > P_{blood} P d ia l ys a t e ​ > P b l oo d ​ ).

This reversed pressure gradient forces dialysate backwards across the membrane into the blood ( backfiltration ). If dialysate contains bacterial fragments or endotoxins, backfiltration sweeps pyrogens into the bloodstream, triggering fever, chills, and inflammation. High-flux treatment makes fluid quality especially important. Ultrapure dialysis fluid (<0.1 CFU/mL and <0.03 EU/mL) is a stricter quality category used in modern practice; distinguish guideline or prescription requirements from the older RD52:2004 minimum incorporated by US CMS. Do not state that every US high-flux treatment is subject to a universal federal ultrapure mandate.

Mass Transfer Area Coefficient ( K o A K_oA K o ​ A )

The mass transfer area coefficient ( K o A K_oA K o ​ A ) is the maximum theoretical clearance (in mL/min \text{mL/min} mL/min ) of a solute (typically urea) at infinite blood and dialysate flow rates: K o A = K o × A K_oA = K_o \times A K o ​ A = K o ​ × A

Where K o K_o K o ​ is membrane permeability and A A A is surface area. High-efficiency dialyzers feature a urea K o A > 800 mL/min K_oA > 800\text{ mL/min} K o ​ A > 800 mL/min (often 1,000 to 1,200 mL/min), providing rapid solute clearance when paired with high blood and dialysate flows.

Dialyzer Classification Comparison

Specification Parameter Low-Flux Dialyzer High-Flux Dialyzer High-Efficiency Dialyzer

K u f K_{uf} K u f ​ ( mL/hr/mmHg \text{mL/hr/mmHg} mL/hr/mmHg ) < 10 < 10 < 10 ≥ 20 \ge 20 ≥ 20 (typically 40 − 80 40-80 40 − 80 ) Variable (often ≥ 20 \ge 20 ≥ 20 )

Pore Diameter / Cutoff < 2 nm < 2\text{ nm} < 2 nm ( < 5 , 000 Da < 5,000\text{ Da} < 5 , 000 Da ) 3 − 5 nm 3-5\text{ nm} 3 − 5 nm ( 20 , 000 − 30 , 000 Da 20,000-30,000\text{ Da} 20 , 000 − 30 , 000 Da ) Variable ( 3 − 5 nm 3-5\text{ nm} 3 − 5 nm )

β 2 M \beta_2\text{M} β 2 ​ M Sieving ( S S S ) ≈ 0.0 \approx 0.0 ≈ 0.0 > 0.60 > 0.60 > 0.60 > 0.60 > 0.60 > 0.60 (if high-flux)

Urea K o A K_oA K o ​ A ( mL/min \text{mL/min} mL/min ) < 600 < 600 < 600 600 − 1 , 200 600-1,200 600 − 1 , 200 > 800 > 800 > 800

  • Ultrafiltration Control Pressure or Volumetric Recommended Precision Volumetric Recommended Volumetric
  • Dialysate Purity Standard AAMI/ISO Recommended Ultrapure Dialysate Recommended Ultrapure
  • Backfiltration Risk Negligible Substantial Substantial (if high-flux)

Flux classifications and the numerical specifications above are illustrative, not a universal definition for every marketed membrane. Check labeled water permeability, clearance and albumin retention for the actual product. Use precise net-UF control with high-permeability dialyzers. Modern ultrapure-fluid guidance reduces pyrogen exposure, but do not confuse that recommendation with the older RD52 standard incorporated into US federal water regulations. High efficiency describes small-solute transfer; high flux describes permeability and middle-solute transfer. They are related but distinct.

Sources checked 2026-10-10: NIDDK HD ; current device and medication instructions govern product-specific details.